SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout!
LGND 206.84+3.8%Nov 24 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: RevMikeB who wrote (23000)7/9/1998 8:51:00 PM
From: Henry Niman  Read Replies (1) of 32384
 
Here's the Science abstract:

A Small, Nonpeptidyl Mimic of Granulocyte-Colony-
Stimulating Factor

Shin-Shay Tian, * Peter Lamb, * Andrew G. King, Stephen G. Miller,
Linda Kessler, Juan I. Luengo, Laurie Averill, Randall K. Johnson,
John G. Gleason, Louis M. Pelus, Susan B. Dillon, Jonathan Rosen

A nonpeptidyl small molecule SB 247464, capable of activating granulocyte-colony-stimulating factor (G-CSF) signal transduction
pathways, was identified in a high-throughput assay in cultured cells. Like G-CSF, SB 247464 induced tyrosine phosphorylation of
multiple signaling proteins and stimulated primary murine bone marrow cells to form granulocytic colonies in vitro. It also elevated
peripheral blood neutrophil counts in mice. The extracellular domain of the murine G-CSF receptor was required for the activity of
SB 247464, suggesting that the compound acts by oligomerizing receptor chains. The results indicate that a small molecule can
activate a receptor that normally binds a relatively large protein ligand.

S.-S. Tian, P. Lamb, L. Kessler, J. Rosen, Department of Transcription Research, Ligand Pharmaceuticals, San Diego, CA
92121, USA. A. G. King, L. Averill, L. M. Pelus, S. B. Dillon, Department of Molecular Virology and Host Defence-US,
SmithKline Beecham Pharmaceuticals, Collegeville, PA 19426, USA. S. G. Miller, Department of New Leads Discovery, Ligand
Pharmaceuticals, San Diego, CA 92121, USA. J. I. Luengo and J. G. Gleason, Department of Medicinal Chemistry-US,
SmithKline Beecham Pharmaceuticals, Collegeville, PA 19426, USA. R. K. Johnson, Department of Oncology, SmithKline
Beecham Pharmaceuticals, King of Prussia, PA 19406, USA.
* These authors contributed equally to this work.

To whom correspondence should be addressed. E-mail: plamb@ligand.com

Related articles in Science:

DRUG DEVELOPMENT:
Small Molecule Fills Hormone's Shoes.
Marcia Barinaga
Science 1998 281: 149-150. (in News of the Week) [Summary] [Full Text]
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext